Sanofi India Signs Partnership with NHM Madhya Pradesh to Expand NCD and Rare Disease Services

Sanofi India's agreement with the National Health Mission (NHM) Madhya Pradesh signals a structured push into public-sector disease management, with operational scope covering non-communicable disease awareness, rare disease screening, and mobile medical unit deployment across the state.

The partnership targets diabetes and broader NCD awareness alongside rare disease identification — two therapeutic areas that place distinct demands on screening infrastructure and supply continuity. Mobile medical units will serve as the primary delivery mechanism, extending diagnostic reach into populations that fall outside conventional facility-based care pathways.

For industry observers tracking public-private collaboration models in India, the arrangement reflects a pattern of originator companies embedding directly within state-level health mission frameworks. NHM Madhya Pradesh operates under the central NHM architecture, meaning programme governance, reporting obligations, and procurement channels follow government health system protocols rather than commercial distribution norms.

Rare disease screening at the community level introduces logistical complexity that differs materially from standard NCD campaigns. Confirmatory diagnostics, referral pathways, and treatment access for rare conditions require coordination across multiple institutional layers — a factor that will shape how the mobile unit programme is designed and evaluated over time.

The agreement's scope, as disclosed, does not specify timelines, patient volume targets, or the rare disease indications prioritised for screening, leaving key programme parameters to be defined through implementation planning.

Execution against the mobile unit deployment schedule will serve as the first measurable indicator of whether the partnership translates stated scope into operational reach across Madhya Pradesh.

Source: Indian Pharma Post via Media4Growth, 7 May 2026.